Edition:
United Kingdom

Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)

SOBIV.ST on Stockholm Stock Exchange

268.70SEK
3:35pm BST
Change (% chg)

-0.20kr (-0.07%)
Prev Close
268.90kr
Open
269.80kr
Day's High
271.30kr
Day's Low
268.50kr
Volume
333,763
Avg. Vol
861,141
52-wk High
299.60kr
52-wk Low
107.40kr

Latest Key Developments (Source: Significant Developments)

Pharma Mar Signs Deal With Impilo Pharma For Yondelis
Friday, 27 Jul 2018 

July 27 (Reuters) - Pharma Mar Sa ::SIGNS DEAL WITH IMPILO PHARMA FOR EXCLUSIVE PROMOTION AND DISTRIBUTION OF YONDELIS IN NORDICS AND EASTERN EUROPE.SAYS WILL RECEIVE AN UP-FRONT PAYMENT OF 2 MILLION EUROS.AGREEMENT WILL REPLACE CURRENT AGREEMENT BETWEEN PHARMA MAR AND SWEDISH ORPHAN BIOVITRUM INTERNATIONAL.  Full Article

Sobi Q2 core profit beats expectations, raises forecast
Wednesday, 18 Jul 2018 

July 18 (Reuters) - Swedish Orphan Biovitrum AB ::Q2 TOTAL REVENUES OF SEK 2,289 M (1,639) FOR Q2.Q2 EBITA INCREASED BY 94 PER CENT TO SEK 951 MLN (492) FOR Q2.SAYS SOBI EXPECTS TOTAL REVENUES FOR FULL-YEAR TO BE IN RANGE OF SEK 8,600-8,800 M (7,900-8,100)..SAYS GROSS MARGIN IS EXPECTED TO BE AT LEAST 70 PER CENT (UNCHANGED).SAYS SOBI EXPECTS EBITA FOR FULL-YEAR TO BE IN RANGE OF SEK 3,400-3,600 M (2,800-3,000).REUTERS POLL: SOBI Q2 EBITA WAS SEEN AT 783 MILLION SEK, REVENUES AT 2,111 MILLION.  Full Article

Sobi raises outlook as Q3 core profit beats expectations
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Swedish Orphan Biovitrum Ab (Publ) :Swedish orphan biovitrum q3 ‍ebita was sek 536 m (282)​.Swedish orphan biovitrum says ‍sobi now expects total revenues for full year to be in range of sek 6,300 to 6,400 m (6,100-6,200)​.Swedish orphan biovitrum says ‍gross margin is expected to be around 70 per cent​.Swedish orphan biovitrum q3 ‍total revenue was sek 1,601 m​.Swedish orphan biovitrum says ‍now expects ebita for full year to be in range of sek 1,900 to 2,000 m (1,700-1,800)​.Swedish orphan biovitrum says ‍growth strategy has been designed to capitalise on substantial potential in haemophilia​.Swedish orphan biovitrum says ‍based on this solid platform we will further balance business with a broader specialty care portfolio to ensure a sustainable company in both short and long-term​.Swedish orphan biovitrum says to decentralise decision making towards the country organisations, resource allocation to support this strategic initiative will be reflected accordingly‍​.Swedish orphan biovitrum says we are rebalancing our geographical footprint in our existing markets by, among other things, scaling and developing our north american franchise‍​.Swedish orphan biovitrum says the strengthening of our late stage research and development pipeline is another key area of focus going forward‍​.Reuters poll: sobi q3 ebita was seen at 509 million sek, revenues at 1,636 million.  Full Article

CORRECTED-Sweden's Sobi buys rights for emapalumab drug, strengthening inflammation business

STOCKHOLM, July 20 Drugmaker Swedish Orphan Biovitrum (Sobi) said on Friday it had reached an exclusive licensing deal with Swiss firm Novimmune SA for the perpetual global rights to emapalumab, a late-stage orphan drug candidate for the treatment of primary Haemophagocytic lymphohistiocytosis.